Inverna Therapeutics will participate in Oligonucleotides for CNS Summit Europe 2026
Inverna Therapeutics is pleased to announce its participation in the Oligonucleotides for CNS Summit Europe 2026, held April 21 – 23, 2026 in Amsterdam, Netherlands.
Connect with Inverna Therapeutics at BIO-Europe Spring 2026 and LSX World Congress Europe 2026
Inverna Therapeutics is pleased to announce its participation in the Life Science Spring Innovation Week 2026, featuring BIO-Europe Spring 2026, held March 23 – 25, 2026, and the directly following LSX World Congress Europe 2026, March 25 – 26, 2026.
Inverna Therapeutics to Showcase Breakthrough Pseudo-Exon Activation Platform at RNA Leaders Europe Congress
Inverna Therapeutics is pleased to announce that Chief Executive Officer, Poul Sørensen, has been invited to present at the RNA Leaders Europe 2026 Congress, taking place from March 17 to 19, 2026, at the Austria Center in Vienna.
Inverna Therapeutics will be presenting at BioCapital 2026
Inverna Therapeutics is pleased to announce that CEO Poul Sørensen will be presenting at the upcoming BioCapital 2026 conference organized by EQT Life Sciences.
Inverna Therapeutics announces the formation of its Scientific Advisory Board consisting of world-renowned leaders in RNA therapeutics and neurodegenerative research
The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.
Inverna Therapeutics awarded grant from the Michael J. Fox Foundation for Parkinson’s research
The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.
Inverna Therapeutics will participate in BIO-Europe 2025
We are excited to participate in BIO-Europe 2025 and are looking forward to connect!
Inverna Therapeutics to showcase its groundbreaking RNA therapeutics platform at Nordic Life Science Days 2025
We are excited to participate in the NLSDays and honored to be selected as a finalist for the Nordic Star Pitch Competition.
Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark
The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.